These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25417465)

  • 1. [Diabetes can even prolong life?].
    Füessl HS
    MMW Fortschr Med; 2014 Oct; 156(17):38. PubMed ID: 25417465
    [No Abstract]   [Full Text] [Related]  

  • 2. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
    Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke.
    Floyd JS; Wiggins KL; Sitlani CM; Flory JH; Dublin S; Smith NL; Heckbert SR; Psaty BM
    Diabetes Obes Metab; 2015 Dec; 17(12):1194-7. PubMed ID: 26179389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
    Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
    Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Summaries for patients. How do older diabetes drugs compare in their effects on heart and blood vessel disease?
    Ann Intern Med; 2012 Nov; 157(9):I-28. PubMed ID: 23128878
    [No Abstract]   [Full Text] [Related]  

  • 7. Diabetes and coronary artery disease: time to stop taking the tablets.
    Edwards RJ; Rakhit RD; Marber MS
    Heart; 1999 Jun; 81(6):674. PubMed ID: 10979714
    [No Abstract]   [Full Text] [Related]  

  • 8. Don't throw the baby out with the bath water: mortality with combination metformin and sulfonylurea.
    Tayek JA
    Diabetes Metab Res Rev; 2007 Feb; 23(2):85-6. PubMed ID: 17262894
    [No Abstract]   [Full Text] [Related]  

  • 9. Does mortality risk vary among sulfonylureas?
    Pantalone KM
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):6-7. PubMed ID: 25466240
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral sulfonylureas and CV mortality.
    Aronow WS
    Geriatrics; 2004 Sep; 59(9):45-6, 49. PubMed ID: 15461238
    [No Abstract]   [Full Text] [Related]  

  • 11. A comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'.
    Chang Y; Choi NK; Hahn S; Park BJ
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1072-3; author reply 1073-4. PubMed ID: 17907252
    [No Abstract]   [Full Text] [Related]  

  • 12. Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke.
    Floyd JS; Wiggins KL; Christiansen M; Dublin S; Longstreth WT; Smith NL; McKnight B; Heckbert SR; Weiss NS; Psaty BM
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):151-60. PubMed ID: 26547662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A lion in the room: Has the CAROLINA trial definitely resolved the issue of the cardiovascular safety of sulfonylureas?
    Koufakis T; Dimitriadis G; Kotsa K
    J Diabetes; 2020 Jul; 12(7):499-502. PubMed ID: 32202061
    [No Abstract]   [Full Text] [Related]  

  • 14. Sulfonylureas and the risk of myocardial infarction.
    Thisted H; Johnsen SP; Rungby J
    Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality risk with sulphonylureas compared to metformin.
    Holden SE; Currie CJ
    Diabetes Obes Metab; 2014 Oct; 16(10):885-90. PubMed ID: 24533964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety of sulphonylurea: comment on the study by Monami et al.
    Du L; Chen Y; Shen J; Peng Y; Sun X
    Diabetes Obes Metab; 2014 Jul; 16(7):667-9. PubMed ID: 24320700
    [No Abstract]   [Full Text] [Related]  

  • 17. Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
    Cho EH; Han K; Kim B; Lee DH
    Medicine (Baltimore); 2020 Jul; 99(29):e21236. PubMed ID: 32702900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study.
    Horsdal HT; Søndergaard F; Johnsen SP; Rungby J
    Pharmacoepidemiol Drug Saf; 2011 Apr; 20(4):331-7. PubMed ID: 21442682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The UK Prospective Diabetes Study.
    Evans M
    Lancet; 1998 Dec; 352(9144):1932-3; author reply 1934. PubMed ID: 9863807
    [No Abstract]   [Full Text] [Related]  

  • 20. The UK Prospective Diabetes Study.
    Bailey CJ; Grant PJ
    Lancet; 1998 Dec; 352(9144):1932; author reply 1934. PubMed ID: 9863806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.